These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 19765439

  • 1. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G, Amirzagar AA, Pourmand G, Mehrsai AR, Taherimahmoudi M, Baradaran N, Nicknam MH, Ebrahimi Rad MR, Saraji A, Asadpoor AA, Moheiydin M, Nikbin B.
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [Abstract] [Full Text] [Related]

  • 2. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
    Truong DQ, Darwish AA, Gras J, Wieërs G, Cornet A, Robert A, Mourad M, Malaise J, de Ville de Goyet J, Reding R, Latinne D.
    Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
    Kim KH, Oh EJ, Jung ES, Park YJ, Choi JY, Kim DG, Lee KY, Kang CS.
    Transplant Proc; 2006 Jun; 38(5):1429-31. PubMed ID: 16797323
    [Abstract] [Full Text] [Related]

  • 4. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
    Kim MS, Kim HJ, Kim SI, Ahn HJ, Ju MK, Kim HJ, Jeon KO, Kim YS.
    Transplantation; 2006 Dec 27; 82(12):1602-5. PubMed ID: 17198243
    [Abstract] [Full Text] [Related]

  • 5. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
    Halim MA, Al-Otaibi T, Al-Muzairai I, Mansour M, Tawab KA, Awadain WH, Balaha MA, Said T, Nair P, Nampoory MR.
    Transplant Proc; 2010 Apr 27; 42(3):801-3. PubMed ID: 20430176
    [Abstract] [Full Text] [Related]

  • 6. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G, Pourmand G, Mehrsai A, Taherimahmoudi M, Nicknam MH, Ebrahimi Rad MR, Seraji A, Asadpoor A, Ansaripor B, Nikbin B, Amirzargar A.
    Iran J Immunol; 2010 Mar 27; 7(1):18-29. PubMed ID: 20371916
    [Abstract] [Full Text] [Related]

  • 7. Association between serum soluble CD30 and serum creatinine before and after renal transplantation.
    López-Hoyos M, San Segundo D, Benito MJ, Fernández-Fresnedo G, Ruiz JC, Rodrigo E, Gómez-Alamillo C, Benito A, Arias M.
    Transplant Proc; 2008 Nov 27; 40(9):2903-5. PubMed ID: 19010142
    [Abstract] [Full Text] [Related]

  • 8. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation.
    Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B.
    Transplantation; 2006 Apr 27; 81(8):1216-9. PubMed ID: 16641611
    [Abstract] [Full Text] [Related]

  • 9. Role of TH1/TH2 cytokines in kidney allograft rejection.
    Karczewski J, Karczewski M, Glyda M, Wiktorowicz K.
    Transplant Proc; 2008 Dec 27; 40(10):3390-2. PubMed ID: 19100396
    [Abstract] [Full Text] [Related]

  • 10. TH1/TH2 cytokine analysis in Iranian renal transplant recipients.
    Amirzargar A, Lessanpezeshki M, Fathi A, Amirzargar M, Khosravi F, Ansaripour B, Nikbin B.
    Transplant Proc; 2005 Sep 27; 37(7):2985-7. PubMed ID: 16213281
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA.
    Transpl Immunol; 2012 Mar 27; 26(2-3):81-7. PubMed ID: 22182633
    [Abstract] [Full Text] [Related]

  • 13. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection.
    Ayed K, Abdallah TB, Bardi R, Abderrahim E, Kheder A.
    Transplant Proc; 2006 Sep 27; 38(7):2300-2. PubMed ID: 16980071
    [Abstract] [Full Text] [Related]

  • 14. Serum T-lymphocyte cytokines cannot predict early acute rejection in renal transplantation.
    Ghafari A, Makhdoomi K, Ahmadpour P, Afshari AT, Lak SS, Fakhri L.
    Transplant Proc; 2007 May 27; 39(4):958-61. PubMed ID: 17524862
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
    Kamali K, Abbasi MA, Farokhi B, Abbasi A, Fallah P, Seifee MH, Ghadimi N, Rezaie AR.
    Exp Clin Transplant; 2009 Dec 27; 7(4):237-40. PubMed ID: 20353374
    [Abstract] [Full Text] [Related]

  • 17. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
    Toren A, Barak V, Novick D, Nagler A.
    Cytokines Cell Mol Ther; 1997 Sep 27; 3(3):153-8. PubMed ID: 9426973
    [Abstract] [Full Text] [Related]

  • 18. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
    Kovac J, Arnol M, Vidan-Jeras B, Bren AF, Kandus A.
    Transplant Proc; 2008 Jun 27; 40(5):1357-61. PubMed ID: 18589105
    [Abstract] [Full Text] [Related]

  • 19. High pretransplantation soluble CD30 levels: impact in renal transplantation.
    Giannoli C, Bonnet MC, Perrat G, Houillon A, Reydet S, Pouteil-Noble C, Villar E, Lefrançois N, Morelon E, Dubois V.
    Transplant Proc; 2007 Oct 27; 39(8):2574-5. PubMed ID: 17954178
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, De Simone P, Berloco P, Molajoni ER.
    Transplantation; 2005 May 15; 79(9):1154-6. PubMed ID: 15880060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.